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Background: Given the rapid expansion of antiretroviral therapy (ART) services in South 
Africa, there is growing recognition of the importance of fertility intentions, contraceptive 
use and childbearing among women living with HIV (WLHIV). With the integration of 
family planning services in the prevention of mother-to-child transmission of HIV (PMTCT) 
services, understanding fertility intentions and contraceptive use is crucial in evaluating such 
programs. We investigated the relationship between future fertility intentions, contraceptive 
use and repeat pregnancies among WLHIV in Cape Town, South Africa. 
Methodology: We analyzed data from the MCH-ART study conducted at the Gugulethu 
Midwife Obstetric Unit (MOU) in Cape Town, South Africa, which followed women 
initiating ART during pregnancy through 36-60 months postpartum. Self-report data were 
collected using standardized questionnaires at repeated study visits. Data on repeat 
pregnancies were abstracted from the Western Cape Provincial Data Centre.  Associations 
between maternal characteristics and repeat pregnancies were examined using Cox 
proportional hazards models. 
Results: Overall, 109 incident repeat pregnancies were recorded among the 471 women 
included in this analysis. The median time at risk per individual was 4.27 years. The rate of 
repeat pregnancies was 5.72 per 100 person-years (PY).  This rate was significantly lower 
among women aged 35-45 years (2.11/100PY) compared to women aged 18-24 years 
[7.56/100 PY; adjusted hazard ratio (aHR), 0.26: 95% confidence interval [CI], 0.09, 0.81). A 
total of 333 women contributed data on future fertility intentions and contraceptive use at 12 
months postpartum, with 9% reporting that they wanted another child in the future, and 82% 
reporting current contraceptive use; 16% (n=54) reported not wanting another child but no 
contraceptive use. The rate of repeat pregnancies was 3 folds higher among women who 
reported wanting a child in the future (12.59/100 PY) compared to women who did not want 
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a child in the future (4.31/100 PY; aHR, 3.46: 95% CI, 1.83, 6.50). Contraceptive use at 12 
months postpartum was not associated with repeat pregnancies. Women who did not want a 
child and used contraceptives had a 45% decreased hazard of repeat pregnancies compared to 
women who did not want a child and did not use contraceptives (aHR 0.55: 95% CI [0.32, 
0.94].  
Conclusion: Among women initiating ART during pregnancy, a repeat pregnancy incidence 
rate of 5.72/100 PY was observed through 36-60 months postpartum, with the incidence 
lower among older women. At 12 months postpartum, a notable proportion of women 
reported not wanting another child but no contraceptive use. Wanting a child in the future 
was associated with a higher rate of repeat pregnancy, but contraceptive use at 12 months 
postpartum was not associated with repeat pregnancies. These results highlight the 
importance of understanding factors associated with the dissonance between fertility 
intentions and contraceptive use and childbearing to ensure delivery of quality integrated 
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Prevention of mother-to-child transmission (PMTCT) of HIV continues to be a public 
health priority following the success of antiretroviral therapy (ART) [1]. Ongoing research 
and programmatic experience have presented cost-effective strategies to reduce the incidence 
of paediatric cases in resource-limited settings [1]. In Sub Saharan Africa, the emphasis is on 
the scaling-up of cost-effective PMTCT interventions to prevent paediatric 
infections. PMTCT interventions in South Africa have been successful covering an estimated 
95% of women living with HIV (WLHIV) [1,4]. 
The World Health Organization (WHO) promotes a comprehensive PMTCT approach 
which includes prevention of HIV among women of childbearing age, preventing unintended 
pregnancies, preventing mother-to-child transmission (MTCT), and providing treatment, 
care, and support to women and their families [1]. To date, the focus has mainly been on 
providing antiretroviral drugs and preventing HIV. There has been less focus on 
understanding the reproductive intentions and contraceptive use among women on ART, 
potentially limiting the ability to prevent unintended pregnancies and to provide care and 
support to WLHIV [1]. 
Women, including WLHIV, have the right to bear the number of children they desire 
with spacing that suits them. Like uninfected women, WLHIV desire additional pregnancies 
and have fertility intentions that change over time. Evidence suggests ART use is associated 
with increased pregnancy incidence [2], although future fertility intentions may increase 
independent of ART use [3]. Research from South Africa has suggested that over one-third of 
women on ART become pregnant [2], and approximately 40 - 50% of women on ART in 
Ethiopia desire to have children [4, 5]. In a study conducted in Kenya between 2003 to 2009, 
the incidence of repeat pregnancies among WLHIV was 17.6 % [6]. Research from South 
Africa and Ethiopia suggests that low levels of education, low economic status and younger 
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maternal age are associated with an increased incidence of repeat pregnancies [6, 7]. Previous 
contraceptive use is associated with decreased odds of repeat pregnancies [4, 6].   
Incidence of pregnancy among WHLIV has important implications for their health, as 
well as their infant’s and partner’s health [8]. Pregnancy without precaution may lead to 
transmission of HIV to their partner and infant [9]. Fertility intentions may have long-term 
consequences on maternal health behaviours such as health-seeking and substance abuse; and 
health trajectories such as depression [8].  Provision of appropriate family planning services 
is important to guide WHLIV through safe conception. In South Africa, women receive 
PMTCT services within the antenatal clinic during pregnancy but are referred to general adult 
ART services immediately postpartum. Provision of family planning services within PMTCT 
programs and general ART services is important in South Africa to prevent the negative 
implications of unplanned pregnancies. Integration of family planning services into PMTCT 
and adult ART services is critical in supporting women’s fertility choices and encouraging 
contraceptive use.  
Evidence suggests that even in developed countries with advanced HIV care, only 
25% of WLHIV discuss future fertility intentions with their health care providers [10]. Lack 
of reproductive health services may lead to an increased incidence of unintended pregnancies, 
the transmission of HIV among serodiscordant couples and increased incidence of mother-to-
child transmission (MTCT) of HIV [1].  
Unintended pregnancies are pregnancies that are unplanned or unwanted or mistimed 
[11]. Prevention of unplanned pregnancies is a crucial aspect of PMTCT, but the incidence of 
unplanned pregnancy remains high globally. For example, an estimated 35% of pregnancies 
in sub-Saharan Africa are unplanned [12].  Unintended pregnancy rate is higher among 
WLHIV compared to the general population [11, 13, 14]. Unplanned pregnancies among 
WLHIV range from 35% to 65% in sub-Saharan Africa and up to two thirds in South Africa 
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[13, 14]. Recent research among women aged 18-35 in South Africa suggests that 50%+ of 
pregnancies among women enrolled in PMTCT programs are unintended [14].  
Unplanned pregnancies are associated with increased risk of maternal depression and 
stress as well as increased risk of adverse birth outcomes such as preterm delivery and 
premature rupture of membranes [11]. A study conducted in South Africa found an increased 
risk of elevated viral load with lower levels of pregnancy intendedness among women 
initiating ART during pregnancy [14]. Unplanned pregnancies are also linked to risky 
behaviours such as substance abuse, delays in entering antenatal care (ANC), and lower 
levels of breastfeeding [14]. 
Findings from a  study conducted among South African women on ART suggest that 
the prevalence of contraceptive use among WLHIV ranges from 25-50% [15]. Contraceptive 
use also changes over time [15]. Specifically, there is a decrease in contraceptive use over 
time [15]. There is often discordance between fertility intentions and contraceptive use 
among WLHIV. Approximately 30 to 40% of WLHIV who do not want children or are 
ambivalent do not use any method of contraception [15]. This suggests gaps in routine care 
and missed opportunities to improve family planning services for WLHIV.   
With adherence to ART, the risk of MTCT is close to zero [1, 16]. Given the high 
incidence of unplanned pregnancies, the discordance between fertility intentions and 
contraceptive use, and the potential implications of repeat pregnancies, we need a better 
understanding of maternal factors associated with repeat pregnancies, and how repeat 
pregnancies are affected by contraceptive use and fertility intentions. Currently, we do not 
have a clear understanding of future fertility intentions and contraceptive use among WLHIV 
and their influences on repeat pregnancies. The lack of conclusive evidence and complexity 





As a result of the scale-up of PMTCT coverage and successful introduction of universal ART 
coverage, paediatric HIV infections have been significantly reduced. However, there is 
limited evidence evaluating the effect of fertility intentions and contraceptive use. Examining 
the effect of contraceptive use and fertility intentions on repeat pregnancies will highlight 
missed opportunities to improve family planning services. In light of the above, there is a 
clear need for more research that explores the association between pregnancy intentions, 
contraceptive use and repeat pregnancies. Also, associations within subgroups such as age, 
socio-economic status and level of education are needed to identify women who are at the 
highest risk.  This research is crucial in evaluating family planning services provided in the 
PMTCT framework and general adult ART services.   
Study Aims and Objectives  
The proposed study aims to investigate the association between future pregnancy intentions, 
contraceptive use and repeat pregnancies in a cohort of ART initiated WLHIV who were 
followed through 36-60 months postpartum.  
The specific objectives are: 
1. To describe the incidence of repeat pregnancies 
2. To explore associations between demographic characteristics and repeat pregnancies  
3. To examine the association between repeat pregnancies and i) future fertility 
intentions and ii) contraceptive use  
4. To investigate the association between a composite measure of future fertility 









The proposed study is a secondary data analysis of the Maternal and Child Health – 
Antiretroviral Therapy (MCH-ART) randomised controlled trial 
(https://clinicaltrials.gov/ct2/show/NCT01933477). Details regarding the MCH-ART study 
are available elsewhere [17]. Briefly, the trial compared different models for delivering HIV 
care to WLHIV during the postpartum period. A total of 471 women were enrolled into the 
trial and were followed postpartum, and an additional follow-up visit was conducted at 36-60 
months postpartum for the “Long-term Adherence and Care Engagement” (LACE) study.  
Analysis set          
The proposed study will include all women enrolled in the postpartum follow-up as part of 
the MCH-ART trial. 
Study setting 
The parent study, MCH-ART, took place at the Gugulethu Midwife Obstetric Unit (MOU), 
where the team has a long history of delivering HIV care and treatment services. LACE was 
set at the Gugulethu Community Health Care Center (CHC), Cape Town, in the same site as 
the parent study. The CHC has provided PMTCT services since 2001.  
Approximately 350 000 people access the facility [17]. The uptake of ANC is consistently 
greater than 95% [17]. The facility serves a population with high levels of poverty, low 
education levels, and a high burden of HIV [18].  Approximately 60% of the population live 
in informal housing. In 2015, 33% of the women attending ANC were HIV positive [18]. 
PMTCT services are integrated into ANC services as per South African national guidelines. 
All women are routinely tested for HIV during their first ANC visit and undergo pre- and 
post-test counselling. Women are referred to general adult ART services during the post-
partum period.  
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Study Population 
This analysis will include all women enrolled into postpartum follow-up for the MCH-ART 
trial, regardless of attendance at the LACE follow-up visit. Importantly, all women had 
initiated ART during pregnancy.  Mother-infant pairs were enrolled within approximately 28 
days post-partum and attended follow-up visits at 6 weeks and 3, 6, 9, 12 and 18 months 
post-partum. A subset attended the LACE study visit at 36-60 months postpartum.  
Inclusion criteria 
• Age ≥18 yrs. 
• Enrolled in postpartum follow-up for the MCH-ART study 
• Initiated ART during pregnancy 
• Provided informed consent  
Exclusion criteria 
• Withdrawn from the MCH-ART study 
• Known maternal death during study follow-up 
• Unable to provide consent  
Data collection 
 
The proposed study will use data collected from mothers enrolled in the postpartum follow-
up as part of the MCH-ART trial. 
a. Enrolment Questionnaires  
Women were enrolled in the study when entering ANC. Standardized questionnaires were 
completed to assess demographics (including age, socio-economic status, level of education) 
and medical history. Pregnancy intentions were assessed at enrolment using the validated 6-
item London Measure of Unplanned Pregnancy (LMUP) tool. The range of possible scores 
sums from 0-12. Scores were categorised into unplanned (0-3), ambivalent (4-9) or planned 
(10-12) according to published scoring guidelines [19]. Future pregnancy intentions and 
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contraceptive use were also assessed at enrolment using a standardized questionnaire. All 
questionnaires were administered by trained interviewers in participants’ home language 
(isiXhosa).  
b.  Assessment of future fertility intentions and contraceptive use 
A standardised questionnaire was administered to assess future pregnancy intentions and 
contraceptive use at enrolment as well as the 12 months visit and 36-60 months visit. Only 
the assessment at the 12 months visit was used for this analysis. Future fertility intentions 
were thus assessed before any repeat pregnancy. Future pregnancy intentions were 
categorised as below;  
• Wants to have a child in the next 12 months 
• Wants to have a child sometime in the future 
• Does not want to have a child in the future 
• Unsure about whether or not wants to have a child in the future 
For this analysis the categories “wants to have a child in the next 12 months” and “wants to 
have a child sometime in the future” have been combined to “wants a child in future” (table 
2).  
The history of contraceptive use was assessed by asking about the method of family planning 
during the last 12 months before the first pregnancy. Contraceptive use was thus assessed 
before any repeat pregnancy. Categories included: the oral contraceptive pill, 2 months 
injectable, 3 months injectable, intrauterine device (IUD), female sterilization, male 
sterilization and female/male condom. This analysis uses contraceptive use reported at 12 
months postpartum. Contraceptive use is be defined as ‘none’ vs ‘any’.  
c. The Abstraction of routinely collected clinical information 
In the parent study, information about subsequent pregnancies including date of delivery and 
delivery outcomes were requested from the Western Cape Provincial Data Centre. The Data 
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Centre stores data from all public sector facilities in the Western Cape. Data are linked across 
facilities using unique patient identifiers. Repeat pregnancy data from non-HIV services were 
excluded. Additional information was abstracted from the MOU and hospital records as 
required.  
 
Table 1. Schedule of measurements to use in the proposed study 
 
 Enrolment visit 
1st Antenatal visit  







Questionnaires     
Demographic and medical 
history 
x   
Family planning use   x  
Future Fertility Intentions  x  
Unplanned pregnancy 
assessment 
x   
Clinical data abstraction     
Antenatal and PMTCT 
information for subsequent 
pregnancies  



















Table.2 Variables to be included in the analysis 
Variable  Scale  Categories 
Maternal Demographics 
Age (years) continuous Quartile category proportions 
Categorical - 
ordinal 
<24, 24-29, 30-39, 40+ 
Education Categorical-
binary 
Finished high school, did not finish high school 





Low, medium, high 
Relationship status Categorical-
binary 





1, 2, ≥3 
Parity Categorical - 
ordinal 
0, 1, ≥2  
HIV 
Viral load (copies/ml) Categorical -
Ordinal 
<50, 50-1000, >1000 
Family planning and reproductive intentions 
Future Fertility intentions Categorical- 
nominal 
Wants a child in future, unsure, doesn’t want a 





unintended, ambivalent, intended 




Birth outcomes Categorical - 
binary 
Repeat pregnancy, no repeat pregnancy 
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Data Management and Analysis  
 
Data Management  
 
Data collected in the parent study (MCH-ART) and the sub-study LACE was entered into a 
custom designed Microsoft access database, maintained in a firewall protected UCT server 
with nightly back-ups. The study database was password protected following standard 
password safety procedures. All study records do not contain participants’ names or personal 
identifiers. Routine data was stored in a separate password protected database using only 
participant study identification numbers. The data used for this proposed study will be stored 
on a password protected computer accessible only to the researcher.  
Data Analysis  
 
Data will be analysed using STATA Version 15.0 (Stata Corporation, College Station, Texas) 
or R (Gnu Project). To describe the data, continuous variables will be summarised using the 
median and IQR. Categorical variables will be summarised using proportions/frequency 
percentages. Chi-square test will be used to compare proportions and rank-sum test for 
median values.  
The incidence rate of repeat pregnancies will be calculated with a 95% confidence interval 
(CI). Crude rates (CR) will be compared as incident repeat pregnancy rate ratios (RR). 
(Objective 1).  Kaplan Meir survival analysis will be used to examine associations between 
maternal characteristics and repeat pregnancy (objective 2). Kaplan Meier survival analysis 
will be used to estimate failure rates (occurrence of repeat pregnancies) by future fertility 
intention categories and contraceptive use categories (objective 3). The log rank test will be 
used to compare survival curves. Proportional hazards model will be used to compare the 
association between composite measure and repeat pregnancy (objective 4).  Potential 
confounders or mediators will be examined before model building. Multivariate models will 
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include all covariates with a significant effect or influence on associations with outcome. 
Standard methods will be used for model diagnostics. 
Ethical considerations 
 
The parent study was approved by The University of Cape Town Faculty of Health Sciences 
Research Ethics Committee (UCT-HREC; REF: 451/2012), the Columbia University 
Medical Center Institutional Review Board (CUMC-IRB) and the research oversight body of 
the provincial government of the Western Cape Department of Health. The LACE sub-study 
was approved by UTC-HREC (REF: 866/2016). Ethical approval for this proposed secondary 
analysis will be sought from UCT-HREC.   
Informed consent  
 
For the MCH-ART and LACE studies, all women provided written informed consent in their 
home language, predominantly isiXhosa. Participants consented to the abstraction of their 
data from routine clinical records. This proposed study will analyse data collected during the 
enrolment and follow-up study visits as well as data already abstracted from routine clinical 
records per consent provided during the MCH-ART and LACE studies.  
Privacy and confidentiality  
 
Analysis in the proposed study will not include personal identifiers. The proposed study will 
ensure confidentiality by not reporting on individual participants or any variable that can be 
linked to an individual participant. 
Risks and benefits 
 
A description of potential risks and benefits, both indirect and direct, within the MCH-ART 
study have been provided and approved by UCT-HREC (REF: 451/2012) 
This proposed study introduces minimal risks primarily due to the loss of confidentiality. 
However, measures have been previously implemented in the parent study and LACE follow-
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up visit to ensure confidentiality. All data included in this analysis and the results presented 
will include no personal identifiers and the data will be securely stored, as described above. 
There are no direct benefits to study participants.  
However, identifying the association between pregnancy intentions, contraceptive use and 
repeat pregnancies has the potential to yield indirect benefits. Increasing knowledge of the 
impact of pregnancy intentions and contraceptive use on repeat pregnancies may be 
important in evaluating the integration of family planning services into PMTCT and shed 
light on missed opportunities to improve family planning services for WLHIV. This may 
considerably benefit the study population as well as other WLHIV in lower middle income 
countries (LMICs). 
Participant compensation  
Since the proposed study involves only secondary data analysis, participants will not receive 
compensation. Participants received compensation for participating in the parent study and 
LACE sub-study. Participants received R150 in grocery vouchers, transport costs, and 
refreshments at study visits, and an educational gift for their child valued up to R100.  
Dissemination of Results 
 
The findings of this proposed study will be valuable in evaluating PMTCT programmes and 
general ART services in South Africa. The manuscript from this analysis will be published in 
a peer-reviewed journal. This way, relevant stake holders such as the Department of Health, 
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Objective of literature review 
 
This section provides a review of existing literature regarding future fertility 
intentions, contraceptive use and repeat pregnancies among women living with HIV 
(WLHIV). Fertility intentions and contraceptive use are presented as predictors of repeat 
pregnancies. In addition, this review summarises relevant knowledge related to trends and 
determinants of future fertility intentions and contraceptive use. These determinants are, inter 
alia, age, parity, and relationship status. This review identifies knowledge gaps and highlights 
research needs. Given that this dissertation uses data from a cohort of women in South 
Africa, this literature review includes only studies that were conducted in sub-Saharan Africa. 
Where appropriate, tables are used to summarise the characteristics and results of selected 
quantitative studies.  
Methodology 
 
Literature for this review was gathered from online peer reviewed journals. PubMed 
(Medline database) was searched for relevant literature, and reference lists were checked for 
additional publications. The search terms are listed below:  
HIV:  Human immunodeficiency virus (HIV), Acquired Immunodeficiency Syndrome 
(AIDS), Mother-to-Child Transmission (MTCT), vertical transmission, Prevention of Mother 
to Child Transmission (PMTCT), Perinatal infections,  
Pregnancy intentions: pregnancy intentions, fertility intentions, reproductive intentions, 
future fertility intentions 
Contraceptives: contraceptive use, family planning, birth control 
Repeat pregnancy: repeat pregnancy, subsequent pregnancy, multiple pregnancies 





We restricted the search to English language publications. No restrictions were made based 
on study design.   
Many studies focused on predictors of future fertility intentions and contraceptive use. Four 
studies included the incidence of pregnancy as an outcome. None of the studies found 
specifically investigated the impact of fertility intentions and contraceptive use on 
repeat pregnancies. The studies included are described table 1.   




Much of the research has focused on fertility intentions related to the current or most 
recent pregnancy. Generally, fertility intentions are categorised into three categories in the 
literature: not wanting more children, unsure and wanting more children. The majority of the 
studies reporting the prevalence of fertility intentions are cross-sectional. The sample 
populations in these studies are comparable, and characteristics are detailed in tables 2 and 4. 
The median age range is 29– 33 years for all studies. In all studies, the majority of women 
had 2 or more children and had low socio-economic status [1-9]. All studies included a group 
of women who had initiated antiretroviral therapy (ART). Across studies, the majority of the 
women had disclosed their HIV status to their partners, except for a study conducted in 
Cameroon which reported that 69% of women had not disclosed their HIV positive status to 
their partner. 
In general, the prevalence of not wanting more children ranges widely in the 
literature, from 45% in Cameroon and Uganda [2], to 71% in South Africa [3] and 95% in 
Malawi [4]. Other studies report a prevalence between these estimates [5-8, 10]. The 
prevalence of wanting more children ranges less widely, from 29% in South Africa [3]  to 
55% in Uganda [2].  
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This review identified three longitudinal studies that reported the prevalence of 
fertility intentions. Studies conducted in Ethiopia and South Africa included pregnant women 
who were not aware of their HIV status at baseline. In these studies, the prevalence of 
wanting children ranged from 32.9% in South Africa to 40.8% in Ethiopia at the beginning of 
the study, and 28.0% in South Africa to 48.3% in Ethiopia at 12 months follow up during the 
pre and postnatal period [7, 11]. The prevalence of wanting children was also similar among 
non-pregnant women in a study conducted in Malawi, with 29% of women reporting that 
they wanted children [12]. 
Determinants of fertility intentions  
 
Intuitively, HIV status and ART use should affect fertility intentions due to improved 
health and sexual desire [13]. Interestingly, among a sample of ART initiated women aged 21 
years or older in Cameroon, women’s subjective perception of their physical health-related 
quality of life (HRQL) influenced their fertility desires [1]. 
 The desire to have children typically declines immediately after knowledge of HIV 
status [7, 11]. In a cohort of  ART naïve women in Malawi, future desire to have children 
declined from 33% to 15 % (p<0.0001) after knowledge of HIV positive results and remained 
constant over the one-year follow-up period [14]. 
There are conflicting results regarding the association between knowledge of a 
partner’s HIV-positive status, one’s own HIV status and ART use. Results from a cohort of 
1766 monogamously married couples in Malawi reported that men and women who know 
their partner’s HIV-positive status are twice as likely to not want more children compared to 
those who did not know, regardless of ART use [15]. However, a cohort of 1855 women in 
Ethiopia showed no correlation between knowledge of a partner’s HIV-positive status and 
fertility intentions [16].  
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A summary of Demographic and Health Surveys (DHS) conducted in nine African 
countries revealed no statistically significant association between knowledge of own HIV-
positive status and the odds of wanting more children. In these studies WLHIV did not differ 
from HIV negative women in terms of their desire for more children [17]. Conversely, in 
Uganda,  WLHIV were less likely to desire children at present and in the near future 
compared to HIV negative women (8% vs 49%; p<0.001) [18, 19]. Furthermore,  WLHIV 
were also less likely to change from not wanting children at baseline to wanting children at 
12 months compared to their HIV negative counterparts [12]. The differences in results 
across these studies could be due to confounding factors such as age and gender. For 
example, the study conducted in Malawi included both men and women in monogamous 
couples, which may differ from results observed among women.  
The desire to have children is consistently reported to be higher among ART initiated 
women compared to ART-Naïve women [1, 7, 16]. For example, women on ART were more 
likely to change from not wanting children to wanting children at 12 months follow up in a 
study conducted in Ethiopia [7]. In South Africa, the duration on ART was reported to be 
associated with fertility intentions among females. In this study, being on ART for 12 months 
or more was associated with a 3-fold increased likelihood of desiring children compared to 
being on ART for less than 6 months [3]. On the contrary, findings from a cohort of 
monogamous couples in Malawi suggest that there is no difference in fertility intentions 
between ART-nitiated and ART-naive participants [15]. This may be due to differences 
across populations.  
Age and the number of live children are very well documented as predictors of 
fertility intentions. Associations with these factors were observed in multiple contexts [1, 3, 
6, 7, 16, 19, 20]. All studies described the reproductive age as 18-49 years. In most studies, 
younger age was associated with an increased desire to have more children. A longitudinal 
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study conducted in Malawi investigating the change from not wanting more children at the 
beginning of the study to wanting more children at the end of 12 months follow up among 
non-pregnant women found that women <20 years old were more likely to change from not 
wanting children to wanting children compared to women aged 30 years [12]. In this study, 
older women were more likely to change to not wanting more children [12]. Conversely, a 
study conducted in Ghana shows an increased desire to have children among women aged 30-
39 years compared to women aged 18-24 years  [20].  
The desire to have children typically declines with an increasing number of living 
children. More specifically, having more than two living children and having more than two 
minor children in the household were associated with decreased odds of desiring more 
children compared to having no living children and having no minor children in the 
household in a study conducted in Uganda [2]. Additionally, women with two or more living 
children were less likely to change from not wanting children to wanting children compared 
to women without children [7, 12].  Women with more living children were more likely to 
change to not wanting more children [12]. 
Much of the literature highlights the importance of couple communication around 
fertility intentions. For example, a male partner’s fertility intentions are found to impact 
women’s fertility intentions [2, 19]. In addition, disclosure of an HIV positive status to one’s 
partner is associated with an increased desire to have children [11]. Conversely, partners may 
choose to not want children after disclosure. Being in a serodiscordant couple is associated 
with a decreased desire to have children [11]. Male partner support is also important in 
women’s desire to have more children. For example, male partner involvement in the mother 
and child care continuum has been reported to be associated with an increased likelihood to 
desire more children among prenatal and postnatal women in South Africa [11]. 
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Although inconclusive, there is evidence suggesting that marital status may affect 
fertility intentions.  In studies conducted in Ethiopia and Malawi, marital status was identified 
as a predictor of fertility intentions. Specifically, single and married women were more likely 
to report a desire to have children compared to divorced/widowed women [4, 7]. Divorced 
and widowed women are reported as being less likely to want children compared to single 
women among both pregnant and non-pregnant women of reproductive age [3, 6, 16]. 
However, an increased desire to have children has been observed among single women 
compared to married women in Kenya [6], whilst no difference was observed between 
married and single women in Ethiopia [16]. Marital status has also been shown to not 
influence changes in fertility intentions from not wanting children to wanting children in 
Malawi [14]. The duration of the relationship possibly modifies the association between 
being in a relationship and fertility intentions compared to being single. In a study conducted 
in South Africa, being in a relationship for less than 5 years increased the odds of wanting a 
child compared to not being in a relationship [3].  
Additionally, having some level of education is associated with an increased 
likelihood to desire a child [16]. Being well informed about HIV disease was also associated 
with wanting a child [1], and information about family planning is associated with fertility 
intentions [2, 11]. In South Africa, a time varying covariate associated with wanting more 
children is lower levels of family planning knowledge. Health care providers have an 
important role in educating women about family planning methods and opening up the 
conversation about fertility intentions among HIV positive women.  Receiving counselling 
from a  health care provider about future pregnancy has been observed to be associated with 






Taken together, the findings summarized above give insights into the trends and 
determinants of fertility intentions. However, the trends of fertility intentions vary widely 
among studies. These may be due to differences in the timing of measurement or differences 
in the context. There are conflicting results on the relationship between knowledge of a 
partner’s HIV-positive status, knowledge of one’s HIV-positive status, ART use and marital 
status and fertility intentions. These discrepancies may be due to the sample sizes, as well as 
differences in study populations and study timing. More longitudinal studies are needed to 
better understand the trends and predictors of fertility intentions (Table 2). Understanding 
trends and determinants of fertility intentions will help identify the need for contraceptive 
use, including the current need as well as unmet needs for contraceptives. This information 










Table 2. Overview of select studies that report on the prevalence of fertility intentions 
among WLHIV 






Atukunda; 2018 Uganda Post-partum 
WHLIV18years 
No  55% desired 
children  
Haddad; 2015 Malawi WLHIV seeking 
family planning 
services 
No  95% did not 
desire more 
children 
Marcelin; 2010 Cameroon HIV + ART 
initiated women 
diagnosed for at 
least 3 months and 
are older than 21 
years old 
No  55% desired 
more children 
Mayhew; 2017 Kenya WLWH Yes 71% did not 
desire more 
children  
Mekonnen; 2017 Ethiopia WLWH Yes  Baseline: 41% 




Myer; 2007 South Africa HIV infected 
women and men 






Ngugi at al;2016 Kenya Sexually active 
women of 15-49 
years 
No  58% did not 
desire children 
in the future 
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O’shea et al; 2015 Malawi HIV infected 
pregnant women 
on ART 18 – 45 
years 
No  1% desired 
additional 
pregnancy in 
next 2 years 
Peltzer et al; 2019 South Africa  HIV infected 
pregnant women 
aged  ≥18 years 
Yes Baseline: 33% 
indicated 
fertility intention 
12 months: 28% 
indicated 





























Generally, contraceptive use is defined as the use of any short-term or long-term birth 
control method during reproductive years (18-49 years). The prevalence of contraceptive use 
ranges widely from 38% in Malawi [18] to 92% in Kenya [6]. Other studies report a 
prevalence in between these estimates [5, 8-10, 18, 21]. Contraceptive use is particularly low 
during the post-partum period [10].  
There seems to be an increase in contraceptive use immediately following an HIV 
positive diagnosis. In a cohort in Malawi, for example, contraceptive use increased from 38% 
to 52% (p<0.0001) one week after diagnosis. In this study, contraceptive use remained 
constant during 3 months of follow up and then decreased over the one year follow up period 
to 46% [14]. In this study, however, it was not specified whether condom use referred to the 
last sex act or every sex act. 
Determinants  
 
Contraceptive use among WLHIV is particularly interesting in this era of universal 
ART coverage. Literature suggests changes in fertility intentions, increased sexual desire and 
sexual activity after ART initiation  [13]. It is interesting to observe if ART initiation also 
affects contraceptive use and if that corresponds with the changing fertility intentions. 
However, definitions of contraceptive use are not standard making it difficult to compare 
results across different settings.  
Evidence regarding the association between HIV status and contraceptive use is 
inconclusive. While several studies have argued that WLHIV have higher levels of 
contraceptive use than their HIV negative counterparts [4, 12, 17, 18], other research has 
shown no variation in contraceptive use by HIV status [5, 10, 22]. Results from a study in 
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rural Mozambique suggest a similar timing of contraceptive initiation as well as resuming 
contraceptive use between WLHIV and HIV-negative and women during the postpartum 
period [10]. Additionally, women in this study who did not initiate or continue using 
contraceptives before the end of the first year of birth were unlikely to use contraceptives at 
all.  
Being younger is associated with a decreased likelihood of using contraception [15, 
18]. However, in rural Mozambique, no association was observed between age and the 
initiation of contraceptive use among postpartum women [10]. The same study also shows 
that older women are more likely to use long-term contraceptive methods such as intrauterine 
devices compared to younger women [10]. However, it is unclear whether age is associated 
with the continuation of contraceptive use.  
The dissonance between fertility intentions and contraceptive use is consistently 
echoed in the existing literature. In a cohort in rural Mozambique, HIV negative women who 
did not desire more children in the future were more likely to start using contraception earlier 
than women who desired more children or who were ambivalent. This pattern is not the same 
in WLHIV, however, with fertility intentions having no influence on contraceptive use 
[10].  This finding is supported by research conducted in Malawi [15] and Kenya [5]. The 
desire to cease childbearing does not seem to influence higher contraceptive uptake [15]. In a 
study conducted in Malawi, 95 % of women reported not wanting more children in the future, 
but only 16% reported using any form of birth control before their most recent pregnancy 
[18]. Across the literature, the majority of women who do not desire another child use 
condoms and short-term contraceptive methods [4, 8, 9, 14, 18]. In a study conducted in 
Malawi, a large proportion of women (24%) reported getting pregnant while using a form of 
family planning [14]. Women using condoms were more likely to report getting pregnant, 
suggesting a need to increase awareness and accessibility of safer contraceptive methods.  
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Knowledge of contraceptive methods and HIV disease are both associated with an 
increased likelihood of contraceptive use. A contraceptive knowledge assessment in Rwanda 
revealed that over 90% of WLHIV knew at least one form of contraceptive. In addition, 
approximately 70% of the women had discussed family planning with a health care provider 
after their recent pregnancy regardless of HIV status [18].  Women who received counselling 
from a health care provider about contraceptive use were more likely to initiate use early and 
to continue using contraceptives [10].  Moreover, the positive impact of HIV disease 
knowledge is greater among women who attend a family planning clinic compared to those 
who don’t [18]. This highlights the unique opportunity that health care providers have to 
increase contraceptive uptake.  
 Similar to fertility intentions, couple communication is important in terms of 
contraceptive use. Couples who agree to not have children are more likely to use 
contraceptives during every sexual act [15]. The positive association between HIV disease 
knowledge and contraceptive use also seems greater among women who disclosed their status 
to their partner [10, 18]. Women in a Sero-discordant couple in a study conducted in Malawi 
were five times more likely to report consistent use of condoms compared to Sero-concordant 
positive partners [14]. Results were similar in a study conducted in Kenya [10]. 
Women with at least secondary school education and women who are 
married/cohabiting were more likely to report contraceptive use [5, 10]. Postpartum women 
who are divorced/widowed/ separated tend to use long-term contraceptive methods such as 
intrauterine devices more so than single/married/cohabiting women [10]. 
Low and inconsistent contraception use has implications for women’s health. It raises 
questions as to whether this is due to structural gaps in reproductive health services for 
WLHIV. Unintended pregnancy is commonly cited as the consequence of low contraceptive 
use and dissonance between fertility intentions and current contraceptive use. In the existing 
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literature, the prevalence of unintended pregnancies ranged from 40% in Kenya [6] to 75% in 
Malawi among women who are aware of their HIV-positive status [8]. In Malawi, the 
prevalence was higher among WLHIV at 49% compared to 37% in HIV uninfected women 
(p=0.004) [8]. 
Younger women are repeatedly reported as being at higher risk of unintended 
pregnancies [9, 22]. Other factors associated with an increased risk of unintended pregnancies 
are being single or divorced, the number of living children and being on ART for longer than 
two years [9, 22]. Having a tertiary education is associated with lower odds of unwanted 
pregnancy and mistimed births [9, 22].   
Rucinski et al studied unmet contraceptive needs in non-pregnant WLHIV on ART 
aged 13-35 years in South Africa. In this study, 50% of the women had a high predicted 
probability of unmet contraceptive needs and this unmet need increased over time [21]. In 
this cohort, one in 10 women were predicted to have unmet contraceptive needs and thus 
were at a higher risk of unintended pregnancy [21].  Limited uptake and discontinuation of 
contraceptives may be due to the fear of side effects in the case of hormonal methods and 
structural barriers such as accessibility and long waiting times [21, 23]. This may impact the 
incidence of pregnancy. 
Synthesis  
 
Overall, the trend of contraceptive use varies widely across studies. Most studies echo the 
dissonance between fertility intentions and contraceptive use. However, there is a lack of 
consistency in the definitions of contraceptive use as shown in table 3. Most studies do not 
specify whether contraceptive use refers to the last sexual act or consistent use. Furthermore, 
more longitudinal studies are needed to better understand the trends and predictors of 
contraceptive use. 
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Table 3. Overview of select studies that report on the prevalence of contraceptive use 
among WLHIV 
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with HIV at 
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Yes Use of any 
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method at 
time of data 
collection 
38% 
Rucinski et al; 
2018 




Yes Not specified 43.2% 
 
 
Trends of pregnancies and repeat pregnancies  
 
Few studies have investigated the incidence of pregnancies among WLHIV. The 
occurrence of pregnancy among WLHIV may be associated with an increased risk of 
virologic failure, maternal complications, maternal death and low retention in care [13, 24]. 
The MTCT risk is highest in low resource settings that fail to retain women through the HIV 
care cascade. A study conducted among WLHIV of reproductive age predicted the incidence 
of pregnancy over 10 years after initiation of ART in West Africa. Eight countries were 
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included in the analysis: Benin, Burkina Faso, Cote d’Ivoire, Gambia, Guinea-Bissau, Mali, 
Nigeria and Senegal [24]. In this analysis, the average crude incidence rate was 2.96 
pregnancies per 100 women-years. The incidence rate of first pregnancy ranged from 1.31 to 
3.46 pregnancies per 100 women-years in Guinea-Bissau and Burkina Faso respectively. 
Three countries had an incidence rate above 3 and five countries below 3 per 100 women-
years. Another study investigating the incidence of pregnancy in seven African countries 
found a higher crude incidence rate of 7.8 incident pregnancies per 100 person years. The rate 
peaked at 21.68 pregnancies per 100 person years in Rwanda [13]. In Malawi, the incidence 
rate was 8.20 pregnancies per 100 women years [25]. The rate was much higher in another 
cohort of WLHIV in Malawi at 14 pregnancies per 100 person years [12]. In this study, there 
were 120 total pregnancies (17%), including 100 first time pregnancies and 20 repeat 
pregnancies [12]. 
Factors associated with pregnancy occurrence 
 
Timing of ART initiation and clinical disease stage affect the rate of incident 
pregnancies. In a study conducted in West Africa, women at an advanced HIV clinical stage, 
WHO stages III and IV, were less likely to report a pregnancy after ART initiation compared 
to women at a less advanced stage [24]. In this study, having a higher CD4 cell count at ART 
initiation increased the risk of first pregnancy. Results from a study of pregnant or recently 
post-partum women in South Africa also support the associations [13].  
Multiple studies have consistently cited age as a predictor of incident pregnancy. In 
the same study in West Africa, younger women had a higher risk of experiencing a first 
pregnancy when compared to women aged 40-49 years. This was especially true among 
women aged 25-29 years, peaking at an estimated 5 pregnancies per 100 women-years [24]. 
In a study conducted in South Africa, women younger than 25 years had double the rate of 
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incident pregnancies compared to women aged 35 years and above. This was true for both 
ART initiated and ART naïve women. In this study, contraceptive use was associated with 
lower rates of pregnancy. This was largely due to hormonal methods. Condom use was 
associated with a higher rate of pregnancy compared to hormonal methods [13].  
The risk of pregnancy has been consistently cited to decrease with increasing number 
of live children [13, 14]. In a study conducted in Malawi, HIV test  results were associated 
with pregnancy incidence [14]. Women who reported wanting more children after receipt of 
HIV positive results had 2.2 times the pregnancy incidence rate [ 95%CI: 1.01 to 4.87] 
compared to those who reported not wanting more children in the future [14]. Overall, there 
is inconclusive evidence about the relationship between the incidence of pregnancy and each 
of marital status and disclosure of HIV positive status.  
Conclusion: Areas for Further Research  
 
Much of the existing literature focuses on predictors of fertility intentions and 
contraceptive use alone. Also, much of the existing literature is dated hence the need for 
further research. Five of the twenty-five papers included in this review are over 10 years old 
and only twelve are less than five years old. More research is needed to make meaningful 
conclusions about the predictors of pregnancies or repeat pregnancies among WLHIV. This 
research will contribute to the body of knowledge on the reproductive health of WLHIV and 
inform interventions that address the reproductive needs of WLHIV and evaluation of 
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associated with wanting less 
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wanting to cease child bearing  
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associated with HIV status, 
partner fertility desires.  
Couples agreeing to stop child 
bearing more likely to use any 
form of contraceptives.   
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Zambia 
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associated with male gender 
and younger age. Decreased 
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fertility desire associated with 
having 2 children or more. 



















589 incident pregnancies 




















Changing from no desire for 
children to desiring children 
associated with ART initiation, 
marital status, disclosure of 
HIV status to partner,  and 
family influence. 
 
Educational status, income, 
partner’s desire to have 
children, partner’s HIV test not 












































HIV status not significantly 
associated with  in fertility 
intentions and contraceptive 



































68.2% FP use. 57.7% did not 
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higher odd AOR 2.27 of 
desiring children in the future.  
[8] O’Shea, 
2015 














HIV infected more likely to 
have no desire for children in 
the future (59% vs 26% 
p<0.001) 
HIV infected women more 
likely to report FP use  
Having >2 children and age 
over 30  associated with 














Face to face 30 
minute survey  
75 % of pregnancies were 
mistimed or unintended. 
Women on ART for 2 years or 
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n=220 ART 18 – 45 
years  
contracepti





more were more likely to have 
unintended pregnancies. 
79% reported use of 
contraceptive. Condom was the 
most common contraceptive.  



















Time invariant covariates 
associated with fertility 
intentions; having no children 
(AOR 0.61 p <0.001), 
Serodiscodant couple or 
unknown partner status 
(AOR=0.76, p<0.01)  
having a partner with 
unknown/HIV-negative status, 
and disclosed HIV status to 
partner (AOR = 1.25, p<0.05) 
 
Time varying covariates 
associated with fertility 
intentions: less family planning 
knowledge (AOR = 0.84, 
p<0.001), counselling with 
health provider about future 
pregnancy (AOR=1.34, 
p<0.01), and male partner 





, South Africa 
2009-2010 Modelling  
n=850  
non pregnant 








on.   
Mathematical 
Modelling  
50% women predicted to have 
high probability of unmet need  
 
1 in 10 women at high risk of 
unintended pregnancy  
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HIV infection significantly 
associated with changes in 
fertility intentions. 
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questionnaires   
69.2% unintended pregnancies  
37.9% did not want a child 
Younger women at  increased 













SECTION C: MANUSCRIPT 




HIV continues to be a global public health priority, especially among women of reproductive age in 
Sub-Saharan Africa [1]. In South Africa, the HIV prevalence among first antenatal care visit attendees was 
29% in 2017 [2]. The expansion of antiretroviral therapy (ART) services has decreased morbidity and 
mortality in the African setting. With this outstanding improvement in life expectancy, there is a growing 
focus on childbearing intentions among women living with HIV (WLHIV).  
Childbearing among WLHIV is important for the following reasons. Firstly, pregnancy without 
precaution may lead to HIV transmission to spouse and infant. Secondly, HIV infection may increase the 
risk of pregnancy complications associated with maternal mortality [3]. Thirdly, fertility intentions may 
influence health behaviours such as health-seeking, ART use and substance use [4]. This highlights the 
importance of addressing reproductive needs of WLHIV.  
 In sub-Saharan Africa, the emphasis has been on the prevention of mother-to-child transmission 
(PMTCT) of HIV through peripartum ART. Shifting the focus to fertility intentions and contraceptive use 
can further reduce the risk of mother-to-child transmission (MTCT) and unintended pregnancies [5]. 
Evidence suggests that WLHIV have higher rates of unintended pregnancies compared to the general 
population [6-8]. Unintended pregnancy among WLHIV range from 35% to 65% in sub-Saharan Africa and 
up to two thirds in South Africa [7, 8]. In South Africa, more than 50% of women aged 18-35 years 
attending PMTCT programs report that their pregnancies were unintended [8].  
To address this, the World Health Organisation (WHO) promotes a comprehensive PMTCT 
approach which includes preventing unintended pregnancies and preventing HIV among women of 
childbearing age [9]. Family planning (FP) is listed as a cost-effective method for decreasing the proportion 
of infants born with HIV [9]. WHO recommends integrating reproductive health services within PMTCT 
interventions and supporting WLHIV to make informed decisions about their reproductive health.  
 HIV care services are in a unique position to address the reproductive health needs of WLHIV 
following WHO’s recommendations. In sub-Saharan Africa, there are increasing efforts to develop 
comprehensive PMTCT programs. However, evidence regarding the predictors of first pregnancy among 
WLHIV is inconclusive, and there are few data on factors influencing repeat pregnancies. To inform such 
 56 
interventions, this study aims to investigate the effect of fertility intentions and contraceptive use on the 
occurrence of repeat pregnancies among WLHIV  in Cape Town, South Africa. We examine the incidence 
of repeat pregnancies and predictors of repeat pregnancy.   
Methods 
 
Study Setting and Population 
 
This secondary analysis uses data from the Maternal Child Health‐Antiretroviral Therapy (MCH-
ART) study (ClinicalTrials.gov NCT01933477), conducted at the Gugulethu Midwife Obstetric Unit (MOU) 
in Cape Town, South Africa [10].  Approximately 5000 women sought antenatal care (ANC) at the MOU in 
2011.  In 2013, 33% of the women attending ANC were HIV positive as per findings from the parent study 
[10]. The population attending the facility is characterised by high levels of poverty, low education levels, 
and a high burden of HIV.   
Inclusion and Exclusion Criteria 
 
As part of the MCH-ART study, women aged ≥18 years were enrolled when entering antenatal care. 
Women who initiated ART during pregnancy were followed through delivery, and women who opted to 
breastfeed were followed through 36-60 months postpartum. Women who withdrew from the parent study 
were excluded from this analysis.  
Data Collection 
 
Self-report data used in this study was collected using standardized questionnaires, including 
demographics, reproductive and medical history. Poverty categories were created using questionnaire data 
about employment status, household assets and type of housing. The categories were as follows; least 
disadvantaged, moderately disadvantaged and most disadvantaged. Pregnancy intentions were assessed at 
enrolment using the validated 6-item London Measure of Unplanned Pregnancy (LMUP) tool. Scores were 
summed for a total score ranging from 0-12. Scores were categorised into unplanned (0-3), ambivalent (4-9) 
or planned (10-12) according to published scoring guidelines [11]. Future fertility intentions and 
contraceptive use were assessed using questionnaires at enrolment as well as the 12 months visit and 36-60 
month visit. This analysis uses future fertility intentions and contraceptive use data collected at the 12 
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months visit. Future fertility intentions appear in the following categories; doesn’t want a child in the future, 
unsure and wants a child in the future. Current contraceptive use at 12 months postpartum is categorised into 
‘none’ vs ‘any’ use. We created a composite variable of future fertility intentions and contraceptive use at 12 
months postpartum, combining those who were unsure about wanting a child in the future with those who 
want a child in the future. The composite measure was categorised as follows; ‘doesn’t want child in the 
future and uses contraceptive’, ‘doesn’t want child in the future and doesn’t use contraceptive’, ‘wants child 
in the future and uses contraceptive’ and ‘wants child in the future and doesn’t use contraceptive’. 
Obstetric outcomes (previous and repeat pregnancies), mode and date of delivery were abstracted from the 
Western Cape Provincial Data Centre. This data center includes all public health facilities in the Western 
Cape. Data are linked across facilities using unique patient identifiers. Repeat pregnancy data from non-HIV 
services were excluded.  Additional information was abstracted from the MOU and hospital records as 
required.  
Data Analysis  
 
Data were analysed using STATA Version 15.0 (Stata Corporation, College Station, Texas) or R 
(Gnu Project). To describe the data, we summarised continuous variables using medians and inter-quartile 
range (IQR). Categorical variables were summarised using frequencies and percentages. Chi square test was 
used to compare proportions across occurrence of repeat pregnancy vs no repeat pregnancy.  The rank sum 
was used to compare median values. 
The incidence rate of repeat pregnancies was calculated with 95% confidence interval (CI). Kaplan Meier 
survival analysis was used to examine associations between maternal characteristics and repeat pregnancy. 
Kaplan Meier survival analysis was used to estimate occurrence of repeat pregnancies by fertility intentions, 
contraceptive use, LMUP scores, and maternal sociodemographic characteristics. Fertility intentions and 
contraceptive use were assessed at 12 months postpartum, and LMUP and sociodemographic characteristics 
at entry into antenatal care. The log rank test was used to compare survival curves. Predictors of repeat 
pregnancies were examined using Cox proportional hazards models. Results were reported as crude and 
adjusted Hazard Ratios (HR) with 95% CI.  
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Table 1. Description of socio-demographic and reproductive health characteristics overall and by  
repeat pregnancy  





Pregnancy – n 
(%) 
No repeat 
pregnancy – n 
(%) 
Number of women  471 109 (23.14) 362(76.86)  
Demographics 
Median [IQR] age (years) 27.80 [24.47 – 
32.25] 





Age category  
18-24  137 (29.09) 40(36.70) 97(26.80) 0.010 
25-34 278 (59.02) 64(58.72) 214(59.12) 
35-45 56 (11.89) 4(4.59) 51(14.09) 
Educational attainment 
Less than secondary 354 (75.16) 80 (73.39) 274 (75.69) 0.627 
Completed secondary/any 
tertiary 
117(24.84) 29 (26.61) 88(24.31) 
Employment status 
Unemployed 287 (60.93) 73 (66.97) 214 (59.12) 0.141 
Employed 184 (39.07) 36(33.03) 148 (40.88) 
Poverty category 
Most disadvantaged 164(34.82) 41(37.61) 123(33.98) 0.676 
Moderate disadvantaged 158 (33.55) 37(33.94) 121(33.43) 
Least disadvantage  149 (31.63) 31(28.44) 118(32.60) 
Relationship status 
Not married/cohabiting 278(59.02) 61(55.96) 217(59.94) 0.459 
Married/cohabiting  193(40.98) 48(44.04) 145(40.06) 
Obstetric characteristics 
Parity  
0 87(18.47) 23(21.10) 64(17.68) 0.116 
1 188(39.92) 50(45.87) 138(38.12) 
≥2 196(41.61) 36(33.03) 160(44.20) 
Fertility intentions and contraceptive use  
Unplanned pregnancy assessment at entry into antenatal care 
Unplanned 278(59.91) 58(54.72) 220(61.45) 0.447 
Ambivalent 92(19.83) 23(21.70) 69(19.27) 
Planned 94(20.26) 25(23.58) 69(19.27) 
Contraceptive use at 12 months postpartum 
None 60(18.02) 19(22.89) 41(16.40) 0.182 
Some 273(81.98) 64(77.11) 209(83.60) 
Future fertility intentions at 12 months postpartum 
Doesn’t want a child in the 
future 
244(63.05) 44(47.83) 200(67.80) 0.001 
Unsure 107(27.65) 32(34.78) 75(25.42) 





Sociodemographic characteristics of the study subjects  
 
A total of 471 WLHIV were included in this analysis (Table 1). The median age was 28 years [IQR: 
24-32]; 75% had less than secondary level education, and most were unemployed. The majority of the 
women were neither married nor cohabiting. 
Reproductive, obstetric, and fertility intentions of study subjects  
 
At enrolment, 464 women completed the LMUP. Unplanned pregnancy was reported by 60% of the 
women; 20% were ambivalent and 20% reported a planned pregnancy. Of the women that reported fertility 
intentions at 12 months postpartum, 63 % (244 of 387) reported not wanting children in the future. Most of 
the women (82%; 273 of 333) reported some form of contraceptive use at 12 months postpartum. Of the 
women with data on fertility intentions and contraceptive use, 54% (179/333) of the women who reported 
not wanting children in the future also reported using some form of contraceptive. However, 16% of the 
women who reported not wanting a child in the future or were unsure reported not using any contraceptive at 
12 months postpartum.  
Table 1 also compares demographic and obstetric characteristics of women who had a repeat 
pregnancy compared to those that did not. Of the women who had a repeat pregnancy, 83% (76/92) reported 
not wanting children in the future or being unsure. Overall, 59% of the women who had a repeat pregnancy 
were between 25-34 years old. There was a significant difference between age categories, with older women 
being less likely to have a repeat pregnancy.  Approximately 59% of women with repeat pregnancies were 
25-34 years old compared to 5% aged 35 to 45 years.  No association was observed between repeat 
pregnancies and other demographic characteristics, LMUP scores at enrolment, or contraceptive use at 12 





Incidence rate of repeat pregnancy  
 
Overall, 109 repeat pregnancies were detected. The incidence rate of repeat pregnancy was 5.72 per 
100 person years (Table 2). The incidence rate of repeat pregnancy appeared to increase with decreasing 
age, with a rate of 2.11 repeat pregnancies per 100 person-years in the 35-45 years category, 5.63 repeat 
pregnancies per 100 person-years in the 25-34 category and 7.56 repeat pregnancies per 100 person-years in 
the 18-24 years category. The incidence rate of repeat pregnancy did not differ according to contraceptive 
use at 12 months postpartum (8.12 repeat pregnancies per 100 person-years among women not using 
contraceptives, versus 5.68 per 100 person-years among those using contraceptives; p=0.18; Figure 1). 
However, the rate of repeat pregnancy differed across future fertility intention categories reported at 12 
months postpartum (Figure 2). The highest rate of repeat pregnancy was observed among those who 
reported that they want a child in the future at 12.59 repeat pregnancies per 100 person-years and the lowest 
rate among those who reported that they do not want a child in the future at 4.31 repeat pregnancies per 100 













Table 2. Crude incidence rates of repeat pregnancy per 100 person-years of observation, with 95% 
CIs according to women’s demographic, socioeconomic, and reproductive characteristics. 
 
Characteristics Incidence rate (95% CI) P-value 
Log-rank test 
Overall 5.72 [4.74, 6.90] - 
Demographics 
Age category  
18-24  7.56 [5.54, 10.30]  
25-34 5.63 [ 4.40, 7.19]  
35-45 2.11 [ 0.88, 5.06]  0.01 
Educational attainment 
Less than secondary 5.68 [4.48, 6.94]  
Completed secondary/any tertiary 6.17 [4.29, 8.89]  0.63 
Employment status 
Unemployed 6.35 [5.05, 7.99]  
Employed 4.77 [3.44, 6.62]  0.14 
Poverty category 
Most disadvantaged 6.23 [4.62, 8.53]  
Moderate disadvantaged 5.75 [4.16, 7.93]  
Least disadvantage  5.11 [3.59, 7.26]  0.68 
Relationship status 
Not married/cohabiting 5.41 [4.21, 6.95]  
Married/cohabiting  6.19 [4.66, 8.21]  0.46 
Obstetric Characteristics 
Parity    
0 6.76 [4.49, 10.17]  
1 6.66 [5.05, 8.78]  
≥2 4.43 [3.20, 6.14]  0.12 
Reproductive Characteristics  
Unplanned pregnancy assessment 
Unplanned 5.12 [3.96, 6.62]  
Ambivalent 6.23 [4.14, 9.28]  
Planned 6.65 [4.49, 9.84]  0.45 
Contraceptive use  
None 8.12[5.18, 12.73]  
Some 5.68 [4.45, 7.26]  0.18 
Future fertility intentions 
Doesn’t a want child in the future 4.31[ 3.31, 5.79]  
Unsure 7.67 [5.42, 10.84]  
Wants a child in the future 12.59 [ 7.72, 20.54]  0.00 
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Figure 1. Kaplan Meier plot: Contraceptive use              Figure 2.  Kaplan Meir plot: Fertility intentions  
 
Factors Associated with incident repeat pregnancies - Table 3 
In univariate proportional hazard models (Table 3), only age and future fertility intentions reported at 
12 months postpartum were identified as significant predictors of repeat pregnancies among WLHIV. These 
associations persisted in the multivariate model presented in table 3. Compared to women aged 18-24 years, 
women aged 35-45 years had a 74% decreased hazard of a repeat pregnancy (aHR:0.26 [0.09, 0.81]). 
Women who were unsure about having a child in the future had a 67% increased hazard of a repeat 
pregnancy compared to women who did not want a child in the future (aHR: 1.67 [1.00, 2.77]). There was a 
3-fold increase in the hazard of a repeat pregnancy among women who wanted a child in the future 
compared to those that did not (aHR: 3.46 [1.83, 6.50]).  
Table 4 presents a proportional hazard model with the composite measure of contraceptive use and 
future fertility intention reported at 12 months postpartum as a predictor. Overall, after adjusting for age, 
parity, employment, poverty category and relationship status; women who reported that they do not want a 
child in the future and reported the use of contraceptives had a 45% decreased hazard of a repeat pregnancy 







Table 3. Cox’s proportional hazards models examining the association between demographic and 
reproductive characteristics and repeat pregnancies presented as HRs with 95% CIs. 
 Crude associations Adjusted associations1 
Characteristics HR (95%CI) P-value HR (95%CI) P-value 
Age  
  18-24 1 (ref)   
  25-34 0.72[0.49, 1.08] 0.11 0.62 [0.38, 1.03] 0.06 
  35-45 0.26 [0.10, 0.66] 0.01 0.26[0.09, 0.81] 0.02 
Educational attainment (ref less than secondary) 
Completed secondary/any tertiary 1.12 [0.73, 1.71] 0.60 1.06 [0.61,    1.83] 0.85 
Poverty category  
Most disadvantaged 1 (ref)   
Moderate disadvantaged 0.91[0.58, 1.41] 0.68 0.83 [0.47,    1.45]
  
0.51 
Least disadvantaged 0.81[0.51, 1.29] 0.38 0.81 [0.45,     1.45] 0.47 
Relationship status (ref not married/cohabiting) 
Married/cohabiting  1.45[0.79, 1.67] 0.48 1.07 [0.64, 01.82] 0.79 
Parity  
  0 1 (ref)   
  1 0.97[0.59, 1.60] 0.92 1.27[0.66, 2.42] 0.47 
  ≥2 0.63[0.37, 1.06] 0.08 1.04[0.50, 2.17] 0.92 
Unplanned pregnancy assessment at entry into antenatal care  
Unplanned 1 (ref)   
Ambivalent 1.26[0.78, 2.04] 0.93 1.18[0.66, 2.13] 0.57 
Planned 1.30[0.81, 2.08] 1.10 0.92[0.51, 1.68] 0.79 
Contraceptive use at 12 months 
postpartum (ref none) 
0.68[0.41, 1.13] 0.14 0.722[0.42, 1.24] 0.24 
Future fertility intentions at 12 months postpartum 
Doesn’t want child in future 1 (ref)   
Ambivalent 1.87 [1.18, 2.94] 0.01 1.67[1.00, 2.77] 0.04 
Wants child in the future 3.37[1.89, 5.98] 0.00 3.46[1.83, 6.50] 0.00 










Table 4. Cox’s proportional hazards models examining the association between composite measure of 
fertility/contraceptive use and repeat pregnancies reported at 12 months postpartum presented as 
HRs with 95% CIs. 
 Crude Association Adjusted Association2 
Composite measure  HR (95%CI) P-value HR (95%CI) P-value 
Doesn’t want child in the future 
and doesn’t use contraceptive 
1 (ref)   
Doesn’t want child in the future 
and uses contraceptive 
0.52 [0.20, 0.87] 0.01 0.55 [0.32, 0.94] 0.03 
Wants child in the future and 
uses contraceptive 
0.84 [0.45, 1.56] 0.58 0.78 [0.42, 1.47] 0.45 
Wants child in the future and 
doesn’t use contraceptive 
1.39 [0.61, 3.15] 0.42 1.35 [0.59, 3.13] 0.48 
2 Multivariate model was adjusted for age, parity, employment, poverty category and relationship status  
Discussion  
 
Our findings suggest an incidence of  more than 5 repeat pregnancies per 100 person-years among 
WLHIV who initiated ART during pregnancy in South Africa. At 12 months postpartum, most women were 
using some form of contraceptives, and the majority did not desire children in the future. However, a large 
proportion of women who reported not wanting a child in the future or were unsure also reported not using 
any contraceptive method. No association was observed between contraceptive use at 12 months postpartum 
and repeat pregnancies, but age and future fertility intentions reported at 12 months postpartum were 
identified as predictors of repeat pregnancies. Wanting a child in the future and being unsure were both 
associated with an increased occurrence of repeat pregnancy.  Nevertheless, almost half of the repeat 
pregnancies occurred among women who reported not wanting a child in the future. 
Prior studies have reported a rate of approximately 3 to 14 incident pregnancies per 100 person years 
[12-15], but these studies investigated incidence of first pregnancy and not repeat pregnancy. As noted in 
other studies conducted in sub-Saharan Africa [12-15], our results indicated that younger women are at a 
higher risk of repeat pregnancy. In this study, 95% of the total repeat pregnancies occurred in women aged 
18-34 (104/109).   A study in 8 countries in West Africa [15] and a study in 7 African countries [12], also 
showed a significantly higher incidence of pregnancy among younger women compared to older women.   
Our results concerning fertility intentions and repeat pregnancies are similar to those from a study 
conducted in Malawi [5], where women who wanted a child were more likely to be pregnant and the 
majority of the pregnancies occurred among women who reported no desire for a future child. Contrary to 
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other studies, contraceptive use was not associated with incident repeat pregnancy in this analysis. This may 
be due to discontinuation of contraceptive use and we did not measure contraceptive use continuation at 12 
months postpartum. The prevalence of contraceptive use is high in this study. However, there may be a 
reliance on short-terms  contraceptive methods e.g. condoms, which may have impacted the association 
between contraceptive use and repeat pregnancy.  Other studies suggest a decreased risk of pregnancy with 
contraceptive use compared to no use [12, 16]. Specifically, hormonal methods are associated with a 
decreased incidence of pregnancy compared to condom use or no use at all [12].   
The dissonance between future fertility intentions and contraceptiveat 12 months postpartum use 
observed in this study highlights the need to understand women’s reproductive desires and contraceptive 
use. Understanding the reasons for this dissonance is important to improve reproductive health services 
integrated in the PMTCT framework or provided in routine care. This information is also crucial in 
evaluating family planning services provided in the PMTCT framework as recommended by WHO. In South 
Africa, 1 in 10 WLHIV were predicted to have a high probability of unmet FP needs that increase over time 
[8] . Low uptake of contraceptives may be due to structural gaps, social and cultural norms and gender 
empowerment issues [17].  To note, contraceptive use in this study was high at 12 months postpartum. 
Routine HIV care services are in a unique position to regularly asses fertility intentions and 
contraceptive use to determine family planning needs of WLHIV. Regularly assessing reproductive health 
needs is important to prevent transmission to partners and unborn infants especially among viraemic women. 
Furthermore, it is an opportunity to provide needed support to prevent unintended pregnancies. Results from 
a study conducted in Kenya support the integration of family planning services into routine HIV care. 
Integration was associated with an increase in family planning uptake among WLHIV [16]. Sensitivity of 
providers to women’s reproductive needs, providing family planning services at the same visit and 
accessibility of a reproductive health room as part of patient flow were identified as factors that encourage 
uptake of contraceptives [16]. 
A major strength of this study is the use of longitudinal data with long-term follow up.  However, 
several limitations should be considered when interpreting findings from this analysis. First, contraceptive 
use and fertility intentions along with other behavioural outcomes were self-reported and are subject to 
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misclassification. To minimise social desirability bias, trained interviewers administered questionnaires in 
private. Second, contraceptive use and fertility intentions were assessed at 12 months postpartum and these 
may change overtime. Third, using routinely collected medical data may lead to underestimating the number 
of repeat pregnancies due to incompleteness. Fourth, the cohort was comprised of primigravida and 
multigravida women. It is unclear whether contraceptive use and fertility intentions would differ in women 
who have never been pregnant. Findings should be generalized to other settings with caution as the data used 
arise from a peri-urban setting and included women from a research study setting. However, we note that 
low levels of contraceptive uptake have been observed in many high burden settings in Sub-Saharan Africa.  
Conclusion  
 
We have demonstrated that age and fertility intentions affect the incidence of repeat pregnancies 
among WLHIV in Cape Town, South Africa. Future research that includes changes in fertility intentions and 
contraceptive use over time is needed to properly estimate the impact on occurrence of repeat pregnancies. 
As women’s health and life expectancy significantly improve after initiating ART, routine screening of 
future fertility intentions and availability of safe contraception methods will be critical in ensuring the 
reproductive health needs of WLHIV are met and unintended pregnancies are averted. Understanding the 
dynamics of fertility among WLHIV is crucial when designing programs integrating reproductive health 
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• Basic and biomedical sciences 
• Behavioural sciences 
• Epidemiology 
• Clinical sciences 
• Health economics and health policy 
• Operations research and implementation sciences 
• Social sciences and humanities, including political sciences and media 
The JIAS prioritizes submissions from operational research and implementation science as publication of such 
material can provide valuable information on various algorithms for monitoring and providing support for 
comprehensive, yet affordable and sustainable treatment, prevention and care programmes in different contexts. 
 
Submission of HIV research carried out in low- and middle-income countries is strongly encouraged. 
 
3. MANUSCRIPT CATEGORIES AND REQUIREMENTS 
The JIAS accepts submissions in the following categories: 
• Research 





• Letter to the Editor 
• Viewpoint 
 
Research - full reports of data from original research studies 
Abstract: 
Headings: Introduction, Methods, Results, Conclusions 
Word limit: 350 words 
Main text: 
Headings: Introduction, Methods, Results, Discussion, Conclusions 
Word limit: 3500 words 
Numbers of figures and tables: Unlimited 
Additional files: Yes 
Download the manuscript template 
 
Short report - brief reports of data from original research, such as follow-up or confirmatory studies, case series and 
negative results 
Abstract: 
Headings: Introduction, Methods, Results and discussion, Conclusions 
Word limit: 350 words 
 
Main text: 
Headings: Introduction, Methods, Results and discussion, Conclusions 
Word limit: 2000 words 
Numbers of figures and tables: 3 
Additional files: No 
Download the manuscript template 
 
Review - comprehensive, authoritative descriptions and summaries of a specific subject area providing a systematic 
and substantial overview of the field 
Abstract: 
Headings: Introduction, Methods, Results and discussion (if applicable, otherwise Discussion only), Conclusions 
Word limit: 350 words 
Main text: 
Headings: Introduction, Methods, Results and discussion (if applicable, otherwise Discussion only), Conclusions 
Word limit: 5000 words 
Numbers of figures and tables: Unlimited 
Additional files: Yes 
Download the manuscript template 
 
Debate - presentation of an evidence-based argument 
Abstract: 
Headings: Introduction, Discussion, Conclusions 
Word limit: 350 words 
 
Main text: 
Headings: Introduction, Discussion, Conclusions 
Word limit: 3500 words 
Numbers of figures and tables: 4 
Additional files: No 
Download the manuscript template 
 
Commentary - focused and opinionated articles on important and timely issues, no original data 
Abstract: 
Headings: Introduction, Discussion, Conclusions 




Headings: Introduction, Discussion, Conclusions 
Word limit: 2500 words 
Numbers of figures and tables: 1 
Additional files: No 
Download the manuscript template 
 






Word limit: 500 words 
Numbers of figures and tables: None 
Additional files: No 
Download the manuscript template 
 






Word limit: 1000 words 
Numbers of figures and tables: 1 
Additional files: No 
Download the manuscript template 
 
4. PREPARING THE SUBMISSION 
Cover letter 
In the cover letter, please explain why your manuscript should be published in the journal. If necessary, address any 
issues relating to our editorial policies .and declare any competing interests (see Editorial Policies and Ethical 
Considerations) 
Parts of the Manuscript 
The manuscript should be submitted as a main text file including figures and appendices and supporting information 
should be supplied as separate files. 
Main Text File 
The text file should be presented in the following order: 
1. Title page; 
2. Keywords; 
3. Abstract; 
4. Main text; 







The title should not contain abbreviations, except commonly used abbreviations such as HIV or AIDS (see Wiley's 
best practice SEO tips ). 
On the title page, you should mention the title of the manuscript, list all authors' names in full, and list any study 
groups if applicable. Each authors' affiliation should be numbered in superscript consecutively and listed 
underneath, including department, institution, city and country. 
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The corresponding author should be marked with the symbol § in superscript and full contact details should be 
provided, including a telephone number with country code. Authors who have contributed equally to the work 
should be marked with the symbol * in superscript. Deceased authors should be marked with the symbol ^ in 
superscript. The email addresses of all authors should be listed by their initials. 
 
Keywords 
Pease provide six keywords. Keywords should be taken from those recommended by the US National Library of 
Medicine's Medical Subject Headings (MeSH) browser list at https://www.nlm.nih.gov/mesh/. Preferably 
alternate words to those found in the abstract in order to improve search hits for the article in repositories. 
Abstract 
The Abstract should not exceed 350 words and should be structured according to the headings of the selected article 
category (see above), excluding the heading “Discussion” for Research articles. Avoid using abbreviations and do not 
cite references in the Abstract. If you are reporting results from a controlled health care intervention, please include 
your trial registry, together with your unique identifying number at the end of the Abstract. For randomized 




The Introduction section should introduce the topic to readers without specialist knowledge in that area and must 
clearly outline the current state of knowledge in this field, the motivation and the aim of the study or the article. 
 
Methods 
The Methods section should include all information necessary to repeat the study, in particular, the study design, 
how data was collected and analyzed, clarifying the choice of methods that were made. If applicable, you should 
describe the setting of the study, the dates the study were conducted, and the sample or participants, as well as 
necessary power calculations and materials, including statistical packages, used. Interventions and programmes 
should be described in detail. Generic names for drugs or any molecules should be used. 
 
All studies involving humans or animals require a statement on ethical approval, and for the former, the consent 
procedure that was followed. Please include the names of the ethics review board(s) that approved the study. If the 
research study was specific to one sex/gender, the reasons for this should be clearly stated. 
 
Results 
This section should include only data and findings from the authors' study. Presentation of statistical results should 
mention confidence intervals and levels of significance where appropriate. Quotes from qualitative study 
participants of less than three lines should be quoted in the text using quotation marks. For quotes longer than three 
lines, place the quote in a separate, indented paragraph and introduce it with a colon. No quotation marks are 
needed in this case. Details of the participant can be added in round brackets following the quote, but should not 
contain identifiable information to ensure confidentiality. Clarifications within the quotation should be placed in 
square brackets. 
 
Submitting authors are strongly encouraged to include data disaggregated by sex (and, whenever possible, by race) 
and provide a comprehensive analysis of gender and racial differences. The authors should include the number and 
percentage of men, women and, if appropriate, transgender persons who participated in the research study. 
Anatomical and physiological differences between men and women (height, weight, body fat-to-muscle ratios, cell 
counts, hormonal cycles, etc.), as well as social and cultural variables (socio-economic, education, access to care, 
etc.), should be taken into consideration in the presentation of data and/or analysis of the results. 
 
Discussion 
In the Discussion section, you should discuss your main findings and place these within the context of the current 
body of knowledge in the field. Limitations of the study, for example, selection bias, can also be discussed, and should 
address how these influence the results and conclusions. If statistically significant differences were found between 
men and women or between different racial or cultural groups in the effects of the studied intervention, the 
implications, if any, for clinical and/or public health should be adequately discussed. 
 
Conclusions 
In your Conclusions section, state your key messages from the study and explain their importance and relevance, as 
well as implications. Future studies and recommendations can be included in this section. The conclusions drawn 
must be strictly based on the data provided. 
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General Style Points 
The following points provide general advice on formatting and style: 
• Abbreviations: In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is 
helpful to the reader. Initially, use the word in full, followed by the abbreviation in parentheses. Thereafter use the 
abbreviation only. 
• Acronyms: Acronyms should be used sparingly, and not in headings or in the Abstract. Only commonly known 
acronyms may be used, and they should be spelt out at first use followed by the abbreviation in brackets. SI units 
should be used, with litre and molar being permitted. 
• Units of measurement: Measurements should be given in SI or SI-derived units. Visit the Bureau International des 
Poids et Mesures (BIPM) website here for more information about SI units. 
• Numbers: Numbers under 10 are spelt out, except for: measurements with a unit (8mmol/l); age (6 weeks old), or 
lists with other numbers (11 dogs, 9 cats, 4 gerbils). 
• Trade Names: Chemical substances should be referred to by the generic name only. Trade names should not be 
used. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to 
these by their generic name, mentioning the proprietary name and the name and location of the manufacturer in 
parentheses. 
• Footnotes: Footnotes are not allowed in the text, the information shall be included directly into the text, where it 
fits best, and if these are references, to include in the reference section at the end. 
• Language: All submissions must be in UK English (International) and UN-accepted terminology should be followed. 
No capitalization should be used except for grammatically correct use, official names and titles, and abbreviations. 
• General recommendation: Use line spacing of 1.5 and an easily readable font, for example, Times New Roman, size 
12. Your manuscript should contain line numbers to facilitate editors' and reviewers' comments 
Wiley Author Resources 
Manuscript Preparation Tips: Wiley has a range of resources for authors preparing manuscripts for submission 
available here . In particular, authors may benefit from referring to Wiley’s best practice tips on Writing for Search 
Engine Optimization . 
Editing, Translation, and Formatting Support: Wiley Editing Services can greatly improve the chances of a 
manuscript being accepted. Offering expert help in English language editing, translation, manuscript formatting, and 
figure preparation, Wiley Editing Services ensures that the manuscript is ready for submission. 
5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS 
Editorial Review and Acceptance 
The acceptance criteria for all papers are the quality and originality of the research and its significance to journal 
readership. Except where otherwise stated, manuscripts are single-blind peer reviewed, meaning that reviewers 
remain anonymous to the authors, although the authors' identity is known to the reviewers. Papers will only be sent 
to review if the Editors-in-Chief determine that the paper meets the appropriate quality and relevance requirements. 
All manuscripts are reviewed by at least two independent experts with experience in the subject area and selected 
by the Editors. Dedicated statistical reviewers may be used if needed. Reviewers have to declare any competing 
interests to the Editors. Authors can suggest peer reviewers during the submission step. Suggested peer reviewers 
should not have co-authored publications with any of the authors during the past five years, should not be current 
collaborators, and should not be members of the same institution. Suggested reviewers will be considered alongside 
potential reviewers identified by the Editorial team. Authors may also request exclusion of individuals as potential 
reviewers: those who have clear competing interests, are close collaborators, or have given input into the 
manuscript previously. 
The Editors assess revised manuscripts based on whether the authors have adequately addressed all comments. Re-
reviews are only requested when revisions fall out of the technical expertise of the Editors. Further rounds of major 
revisions are usually not allowed, and manuscripts that have not been satisfactorily revised will be rejected. Minor 
revisions though may be requested as needed. 
 
Wiley's policy on the confidentiality of the review process is available here. 
 
Data Storage and Documentation 
The Journal of the International AIDS Society expects that data supporting the results in the paper will be archived in 
an appropriate public repository. Whenever possible the scripts and other artefacts used to generate the analyses 
presented in the paper should also be publicly archived. Exceptions may be granted at the discretion of the editor for 
sensitive information such as human subject data or the location of endangered species. Authors are expected to 
provide a data accessibility statement, including a link to the repository they have used, to accompany their paper. 
 
Protein and nucleotide sequences 
For nucleic acid sequences, protein sequences or atomic coordinates, which are cited in the manuscript, and the 
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accession number, together with the database where the information was deposited, should be cited in square 
brackets in the text, for example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, 
PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116]. Relevant databases are: EMBL Nucleotide Sequence Database (EMBL), 
DNA Data Bank of Japan (DDBJ), GenBank at the NCBI (GenBank), Protein Data Bank (PDB), Protein Information 
Resource (PIR) and the Swiss-Prot Protein Database (Swiss-Prot). 
 
Mass spectrometry 
Mass spectrometry data should be provided in the mzML format according to the HUPO Protein Standards 
Initiative Mass Spectrometry Standards Working Group guidelines. The data should also be deposited in 
the ProteomeExchange through the PRIDE website, and protein interaction data can be deposited through 
members of the IMEx consortium. 
 
Structures 
Protein structures can be submitted with one of the members of the Worldwide Protein Data Bank. Nucleic acid 
structures can be deposited with the Nucleic Acid Database at Rutgers. Crystal structures of organic compounds 
can be deposited with the Cambridge Crystallographic Data Centre. 
 
Chemical structures and assays 
Structures of chemical substances can be deposited with PubChem Substance. Bioactivity screens of chemical 
substances can be deposited with PubChem BioAssay. 
 
Functional genomics data (such as microarray or CHIP-Seq data) 
Please refer to standards proposed by the Functional Genomics Data Society and deposit your microarray data in 
MIAME-compliant format in one of the public repositories, for example, ArrayExpress or Gene Expression 
Omnibus (GEO). Deposition of high-throughput functional genomics sequencing data (such as RNA-Seq or ChIP-Seq 
data) with ArrayExpress or GEO in compliance with MINSEQE is also needed. 
Computational modelling 
Please prepare models of biochemical reaction networks using the Systems Biology Markup Language and submit 
your model to the BioModels database, as well as providing it as an additional file with your submission. 
 
Plasmids 
Please submit copies of your plasmids as DNA or bacterial stocks with Addgene, a non-profit repository, 
or PlasmID, the Plasmid Information Database at Harvard. 
Ethical approval – Human and animal studies 
 
Human Studies and Subjects 
For manuscripts reporting medical studies that involve human participants, a statement identifying the ethics 
committee that approved the study and confirmation that the study conforms to recognized standards is required, 
for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European 
Medicines Agency Guidelines for Good Clinical Practice. 
A statement on the ethical aspects, including the consent procedure followed, must be included in the Methods 
section of the manuscript. The Editors may reject manuscripts where the research has not been carried out within an 
ethical framework. Images and information from individual participants will only be published where the authors 
have obtained the individual's free prior informed consent. Confidentiality of study participants must be ensured at 
all stages of research and reporting. Authors do not need to provide a copy of the consent form to the publisher; 
however, in signing the author license to publish, authors are required to confirm that consent has been obtained. 
Wiley has a standard patient consent form available for use. 
Animal Studies 
A statement indicating that the protocol and procedures employed were ethically reviewed and approved, as well as 
the name of the body giving approval, must be included in the Methods section of the manuscript. Authors are 
encouraged to adhere to animal research reporting standards, for example the The Gold Standard Publication 
Checklist from Hooijmans and colleagues or the ARRIVE reporting guidelines for reporting study design and 
statistical analysis; experimental procedures; experimental animals and housing and husbandry. Authors should also 
state whether experiments were performed in accordance with relevant institutional and national guidelines for the 
care and use of laboratory animals: 
• US authors should cite compliance with the US National Research Council's Guide for the Care and Use of 
Laboratory Animals, the US Public Health Service's Policy on Humane Care and Use of Laboratory Animals, 
and Guide for the Care and Use of Laboratory Animals. 
• UK authors should conform to UK legislation under the Animals (Scientific Procedures) Act 1986 Amendment 
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Regulations (SI 2012/3039). 
• European authors outside the UK should conform to Directive 2010/63/EU. 
Clinical Trial Registration 
The journal requires that clinical trials are prospectively registered in a publicly accessible database and clinical trial 
registration numbers should be included in all papers that report their results. Authors are asked to include the 
name of the trial register and the clinical trial registration number at the end of the abstract. If the trial is not 
registered, or was registered retrospectively, the reasons for this should be explained. 
 
Research Reporting Guidelines 
Standard of reporting 
The JIAS endorses international standards of reporting. Please see the Uniform Requirements for Manuscripts 
Submitted to Biomedical Journals guidelines produced by ICMJE as a reference standard of reporting. Authors are 
also referred to the EQUATOR network website for further information on the available reporting guidelines for 
health research, and the MIBBI Portal for prescriptive checklists for reporting biological and biomedical research 
where applicable. A number of checklists are available for various study designs, including randomized controlled 
trials (CONSORT), interventional trials (SPIRIT), qualitative research (COREQ), systematic reviews (PRISMA), 
observational studies (STROBE), economic evaluations of health interventions (CHEERS), meta-analyses of 
observational studies (MOOSE) and diagnostic / prognostic studies (STARD and TRIPOD ). For systematic reviews, 
an additional file should be provided by the authors listing all details concerning the search strategy. Please refer to 
the Cochrane Reviewers' Handbook for an example of how a search strategy should be presented. 
 
Guidelines on mutation nomenclature are provided by the Human Genome Variation Society , and authors should 
use the recommended gene name by referring to the appropriate genetic nomenclature database, for example, HUGO 
for human genes, and the International Committee on Standardized Genetic Nomenclature for Mice. When describing 
human phenotypes, please use standardized terms, such as those proposed by the Elements of Morphology working 
group (see http://research.nhgri.nih.gov/morphology/index.cgi ). 
Contributions from pharmaceutical companies or other commercial organizations should follow the Good 
Publication Practice guidelinEs for pharmaceutical companies, which also apply to any companies or 
individuals that work on industry-sponsored publications, such as freelance writers, contract research organizations 
and communications companies. 
The JIAS supports international standards of reporting of trials, in particular, prospective registering and numbering 
of clinical trials. Clinical trials are defined by the World Health Organization as all phase I to IV trials, which are 
research studies that prospectively assign human participants or groups of humans to one or more health-related 
interventions to evaluate the effects on health outcomes. Trials need to be registered prior to submission in a 
suitable, publicly available registry. Links to existing registries can be found through ICMJE here or through the 
primary registers that participate in the WHO International Clinical Trials Registry Platform. The trial 
registration number should be included as the last line of the manuscript Abstract. 
 
Reporting by gender and race 
Submitting authors shall include data disaggregated by sex (and, whenever possible, by race) and provide an 
analysis of gender and racial differences. The authors should include the number and percentage of men, women 
and, if appropriate, transgender persons, who participated in the research study. Anatomical and physiological 
differences between men and women (height, weight, body fat-to-muscle ratios, cell counts, hormonal cycles, etc.), as 
well as social and cultural variables (socio-economic, education, access to care, etc.), should be taken into 
consideration in the presentation of data and/or analysis of the results. If statistically significant differences were 
found between men and women or between different racial or cultural groups in the effects of the studied 
intervention, the implications, if any, for clinical and/or public health should be adequately discussed. If the research 
study was specific to one sex/gender, the reasons for this should be clearly stated. Please refer to the SAGER 
guidelines for more information 
 
Species Names 
Upon its first use in the title, abstract, and text, the common name of a species should be followed by the scientific 
name (genus, species, and authority) in parentheses. For well-known species, however, scientific names may be 
omitted from article titles. If no common name exists in English, only the scientific name should be used. 
Genetic Nomenclature 
Sequence variants should be described in the text and tables using both DNA and protein designations whenever 
appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see varnomen.hgvs.org, 
where examples of acceptable nomenclature are provided. 
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